Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 3/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | CEL | P19835 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348009 | 1.00 | SIGMAR1 (0.54) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7458143 | 1.00 | SIGMAR1 (0.54) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL17027405 | 1.00 | SIGMAR1 (0.54) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7453118 | 1.00 | SIGMAR1 (0.54) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL98103 | 1.00 | SIGMAR1 (0.54) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7457427 | 1.00 | SIGMAR1 (0.54) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7457536 | 1.00 | SIGMAR1 (0.54) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7458663 | 1.00 | SIGMAR1 (0.54) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7452816 | 1.00 | SIGMAR1 (0.54) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7350448 | 0.98 | SIGMAR1 (0.50) | SIGMAR1CYP1A2KDM5APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310411-A1 | METHODS OF TREATMENT FOR A KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-05 | — | — | US | disclosed |
| US-20130203790-A1 | SULFUR-CONTAINING COMPOUNDS AS ANTI-PROLIFERATIVE AGENTS | 221076 ONTARIO INC. (CA) | 2013-08-08 | — | — | US | disclosed |
| WO-2013006971-A1 | SULFUR-CONTAINING COMPOUNDS AS ANTI-PROLIFERATIVE AGENTS | 221076 ONTARIO INC. (CA) | 2013-01-17 | — | — | WO | disclosed |
| US-20110166114-A1 | METHOD FOR TREATING SNORING AND SLEEP APNEA WITH LEUKOTRIENE ANTAGONISTS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION | 2011-07-07 | — | — | US | disclosed |
| US-20090317476-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LEUKOTRIENE RECEPTOR ANTAGONIST FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS, LLC | 2009-12-24 | — | — | US | disclosed |
| US-20060194840-A1 | Method for treating snoring and sleep apnea with leukotriene antagonists | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION | 2006-08-31 | — | — | US | disclosed |
| EP-1653910-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LEUKOTRIENE RECEPTOR ANTAGONIST FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Epigenesis Pharmaceuticals LLC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050101544-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS, LLC | 2005-05-12 | — | — | US | disclosed |
| WO-2005027853-A2 | METHOD FOR TREATING SNORING AND SLEEP APNEA WITH LEUKOTRIENE ANTAGONISTS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005011595-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LEUKOTRIENE RECEPTOR ANTAGONIST FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS LLC (US) | 2005-02-10 | — | — | WO | disclosed |
| US-5270324-A | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-12-14 | — | — | US | disclosed |
| US-5266568-A | Hydroxyalkylquinoline ether acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-11-30 | — | — | US | disclosed |
| WO-1993021169-A1 | BENZOTHIAZOLE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021168-A1 | THIAZOLE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021158-A1 | PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| US-5202321-A | Antihistamine, antiallergens, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1993-04-13 | — | — | US | disclosed |
| EP-0518426-A1 | Thiopyrano (2,3,4-c,d) indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1992-12-16 | — | — | EP | disclosed |
| EP-0480717-A1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| EP-0480708-A2 | Hydroxyalkylquinoline ether acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| EP-0480716-A1 | Saturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101544-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease | LTB4R, LTB4R2, CYSLTR1 | SIGMAR1 932/4885CYP1A2 645/4885KDM5A 1285/4885 |
| US-20060194840-A1 | Method for treating snoring and sleep apnea with leukotriene antagonists | LTB4R2, LTB4R, CYSLTR2 | SIGMAR1 685/4885CYP1A2 989/4885KDM5A 3434/4885 |
| US-20130203790-A1 | SULFUR-CONTAINING COMPOUNDS AS ANTI-PROLIFERATIVE AGENTS | MKI67, TST, PCNA | SIGMAR1 925/4885CYP1A2 4815/4885KDM5A 2587/4885 |
| US-20110166114-A1 | METHOD FOR TREATING SNORING AND SLEEP APNEA WITH LEUKOTRIENE ANTAGONISTS | LTB4R2, LTB4R, CYSLTR2 | SIGMAR1 685/4885CYP1A2 989/4885KDM5A 3434/4885 |
| US-20230310411-A1 | METHODS OF TREATMENT FOR A KIDNEY DISEASE | LTB4R2, LTB4R, ALOX5 | SIGMAR1 1997/4885CYP1A2 2489/4885KDM5A 3134/4885 |
| US-20090317476-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LEUKOTRIENE RECEPTOR ANTAGONIST FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | LTB4R, LTB4R2, CYSLTR1 | SIGMAR1 932/4885CYP1A2 645/4885KDM5A 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.